A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching from Treatment with 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment.

Project: Research

StatusActive
Effective start/end date16/04/1931/12/24

Keywords

  • Neurological disorders
  • Multiple sclerosis (MS)
  • Clinical trial
  • Neurological disorders
  • Multiple sclerosis (MS)
  • Clinical trial
  • Neurological disorders
  • Multiple sclerosis (MS)
  • Clinical trial